IP Library › Granted Patent US 12703856
Granted Patent B2
US 12703856 · App. 18/630,991 · Granted Aug 11, 2026

Methods for reducing elevated glucose levels

Inventors: Gerald Swiss (Mill Valley, CA); David Kiewlich (Mill Valley, CA)
Assignee: SDF BioPharma, Inc
C12N5/0676A61K35/17A61K35/39A61P3/10C07K14/522C12N5/0635C12N5/0638C12N5/0646C12N5/0686C12N2501/998C12N2502/11C12N2502/99C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12703856
App. No.
18/630,991
Granted
Aug 11, 2026
Kind
B2
Abstract

Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.

Claims (18)

1 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a population of human beta cells that expresses or overexpresses a human fugetactic agent in an amount sufficient to render said beta cell resistant to human immune cells, wherein said beta cell is capable of expressing insulin.

2 . The pharmaceutical composition according to claim 1 , wherein said human beta cell comprises a vector that itself comprises a nucleic acid sequence encoding human CXCL12 wherein said beta cell is resistant to human immune cells.

3 . The pharmaceutical composition according to claim 1 , wherein said human beta cell is an autologous beta cell obtained from a subject with type 1 diabetes.

4 . The pharmaceutical composition according to claim 1 , wherein said human beta cell is an allogenic beta cell.

5 . The pharmaceutical composition according to claim 1 , wherein said human immune cells comprise NK cells, cytotoxic T cells and/or B cells.

6 . The pharmaceutical composition according to claim 1 , wherein said human beta cell expresses human CXCL12 at a fugetactic amount.

7 . The pharmaceutical composition according to claim 1 , wherein said CXCL12 is selected from the group consisting of CXCL12 alpha and CXCL12 beta.

8 . The pharmaceutical composition according to claim 1 , wherein said human beta cell comprises a transgenic regulatory region upstream of an endogenous CXCL12 coding region wherein said beta cell is resistant to human immune cells.

9 . The pharmaceutical composition according to claim 8 , wherein said human beta cell is an autologous beta cell.

10 . The pharmaceutical composition according to claim 8 , wherein said human beta cell is an allogenic beta cell.

11 . The pharmaceutical composition according to claim 8 , wherein said human beta cell is an autologous beta cell obtained or derived from a subject with type 1 diabetes.

12 . The pharmaceutical composition according to claim 9 , wherein said human beta cell is an allogeneic beta cell obtained or derived from a subject free of type 1 diabetes.

13 . The pharmaceutical composition according to claim 8 , wherein the transgenic regulatory region is an exogenous constitutive, or inducible promoter.

14 . The pharmaceutical composition according to claim 8 , wherein said human beta cell expresses human CXCL12 beta.

15 . The pharmaceutical composition according to claim 1 , wherein said human beta cell is incapable of cell division.

16 . The pharmaceutical composition according to claim 1 , wherein the human CXCL12 is selected from the group consisting of CXCL12 alpha, CXCL12 beta, CXCL12 delta, and CXCL12 gamma.

17 . The pharmaceutical composition according to claim 1 , wherein said human immune cells comprise NK cells, cytotoxic T cells and B cells.

18 . The pharmaceutical composition according to claim 1 , wherein said pharmaceutical excipient is a sterile aqueous solution.